Bristol-Myers Worldwide Consumer Health Sales Jump 13%
This article was originally published in The Tan Sheet
Executive Summary
Foreign sales gains in the Bufferin analgesic line - most notably in Japan - helped Bristol-Myers Squibb's worldwide consumer drug sales see a 13% increase to $274 mil. in the second quarter, the company reported July 20. Excluding foreign exchange, the segment's revenues jumped 17%.
You may also be interested in...
BMS Streamlining To Focus On Consumer Medicines, Nutritionals
Bristol-Myers Squibb's decision to divest its Clairol cosmetics and Zimmer orthopedic implants businesses in the next 6 to 12 months is part of the company's strategy to focus its resources on its core medicines segments.
BMS Streamlining To Focus On Consumer Medicines, Nutritionals
Bristol-Myers Squibb's decision to divest its Clairol cosmetics and Zimmer orthopedic implants businesses in the next 6 to 12 months is part of the company's strategy to focus its resources on its core medicines segments.
BMS Streamlining To Focus On Consumer Medicines, Nutritionals
Bristol-Myers Squibb's decision to divest its Clairol cosmetics and Zimmer orthopedic implants businesses in the next 6 to 12 months is part of the company's strategy to focus its resources on its core medicines segments.